血浆铁蛋白作为社区获得性肺炎危重患者巨噬细胞活化样综合征的标志物
这项前瞻性观察性队列研究在荷兰两家三级医院ICU纳入153例社区获得性肺炎患者,按入院血浆铁蛋白>4420 ng/mL分为巨噬细胞活化样综合征组(n=15,9.8%)和对照组(n=138,90.2%)。巨噬细胞活化样综合征组病情更重,ICU死亡率更高(46.7% vs 12.3%,p=0.002),23种反映宿主反应通路失调的血浆生物标志物紊乱更明显。血液恶性肿瘤在巨噬细胞活化样综合征组占比更高(33.3% vs 5.1%,p=0.001)。排除血液恶性肿瘤患者(n=141)后,死亡率差异不再存在,但宿主反应异常仍持续。提示铁蛋白>4420 ng/mL在社区获得性肺炎危重患者中识别的巨噬细胞活化样综合征与血液恶性肿瘤密切相关,并伴随多通路宿主反应失调。
要点
- 社区获得性肺炎危重患者中,入院铁蛋白>4420 ng/mL定义的巨噬细胞活化样综合征发生率为9.8%(15/153)。
- 巨噬细胞活化样综合征组ICU死亡率46.7%,显著高于对照组12.3%(p=0.002)。
- 血液恶性肿瘤在巨噬细胞活化样综合征组占33.3%,对照组占5.1%(p=0.001)。
- 排除血液恶性肿瘤患者(n=141)后,两组死亡率差异不再存在,但宿主反应异常仍持续。
- 23种反映全身炎症、细胞因子反应、内皮细胞活化与屏障功能、凝血激活的血浆生物标志物在巨噬细胞活化样综合征组紊乱更明显。
适用人群与场景
- 荷兰两家三级医院ICU收治的社区获得性肺炎危重患者,共153例。
- 排除标准未在摘要中报告。
诊断标准与关键阈值
- 巨噬细胞活化样综合征定义为入院血浆铁蛋白水平>4420 ng/mL。
- 对照组为入院血浆铁蛋白水平≤4420 ng/mL的社区获得性肺炎患者。
研究设计与关键结果
- 研究类型:前瞻性观察性队列研究;场所:荷兰两家三级医院ICU;样本量:153例社区获得性肺炎患者。
- 分组:巨噬细胞活化样综合征组n=15(9.8%),对照组n=138(90.2%),按入院血浆铁蛋白>4420 ng/mL或≤4420 ng/mL划分。
- 主要结局:巨噬细胞活化样综合征组病情更重,ICU死亡率46.7% vs 对照组12.3%(p=0.002)。
- 生物标志物:23种反映全身炎症、细胞因子反应、内皮细胞活化与屏障功能、凝血激活的血浆生物标志物在巨噬细胞活化样综合征组紊乱更明显。
- 血液恶性肿瘤:巨噬细胞活化样综合征组33.3% vs 对照组5.1%(p=0.001)。
- 亚组分析:排除血液恶性肿瘤患者后(n=141),死亡率差异不再存在,但巨噬细胞活化样综合征组宿主反应异常仍持续。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在社区获得性肺炎危重患者中,入院铁蛋白>4420 ng/mL可识别出巨噬细胞活化样综合征表型,该组病情更重、ICU死亡率更高,且常合并血液恶性肿瘤。
- 排除血液恶性肿瘤后死亡率差异消失,提示铁蛋白升高在此人群中的预后意义可能与血液恶性肿瘤相关;原文未据此给出治疗推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Plasma ferritin levels above 4,420 ng/mL have been proposed as a diagnostic marker for macrophage activation-like syndrome in sepsis and used for selection of sepsis patients for anti-inflammatory therapy. We here sought to determine the frequency, presentation, outcome, and host response aberrations of macrophage activation-like syndrome, as defined by admission ferritin levels above 4,420 ng/mL, in critically ill patients with community-acquired pneumonia.
DESIGN: A prospective observational cohort study.
SETTING: ICUs in two tertiary hospitals in the Netherlands.
PATIENTS: One hundred fifty-three patients admitted with community-acquired pneumonia.
MEASUREMENTS AND MAIN RESULTS: Patients were stratified in community-acquired pneumonia-macrophage activation-like syndrome (n = 15; 9.8%) and community-acquired pneumonia-control groups (n = 138; 90.2%) based on an admission plasma ferritin level above or below 4,420 ng/mL, respectively. Community-acquired pneumonia-macrophage activation-like syndrome patients presented with a higher disease severity and had a higher ICU mortality (46.7% vs 12.3% in community-acquired pneumonia-controls; p = 0.002). Twenty-three plasma biomarkers indicative of dysregulation of key host response pathways implicated in sepsis pathogenesis (systemic inflammation, cytokine responses, endothelial cell activation, and barrier function, coagulation activation) were more disturbed in community-acquired pneumonia-macrophage activation-like syndrome patients. Hematologic malignancies were overrepresented in community-acquired pneumonia-macrophage activation-like syndrome patients (33.3% vs 5.1% in community-acquired pneumonia-controls; p = 0.001). In a subgroup analysis excluding patients with hematologic malignancies (n = 141), differences in mortality were not present anymore, but the exaggerated host response abnormalities in community-acquired pneumonia-macrophage activation-like syndrome patients remained.
CONCLUSIONS: Macrophage activation-like syndrome in critically ill patients with community-acquired pneumonia occurs more often in patients with hematologic malignancies and is associated with deregulation of multiple host response pathways.
参考来源
- Brands X, de Vries FMC, Uhel F, et al. Plasma Ferritin as Marker of Macrophage Activation-Like Syndrome in Critically Ill Patients With Community-Acquired Pneumonia. Crit Care Med. 2021. PMID: 33935163. doi:10.1097/CCM.0000000000005072
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。